ArticleMedical physics2025
Implementation of a novel pencil beam scanning Bragg peak FLASH technique to a commercial treatment planning system.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Breathing-phase selection for gated proton therapy in lung cancer towards temporally targeted ultra-high dose rate delivery.Physics and imaging in radiation oncology · 2026Article
- Review
- Article
- Implementation of a novel pencil beam scanning Bragg peak FLASH technique to a commercial treatment planning system.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUltra-high dose rate, or FLASH, radiotherapy has shown promise in preclinical experiments of sparing healthy tissue without compromising tumor control. This "FLASH effect" can compound with dosimetric sparing of the proton Bragg peak (BP) using a method called Single Energy Pristine Bragg Peak (SEPBP) FLASH. However, this and other proposed FLASH techniques are constrained by lack of familiar treatment planning systems (TPSs). Creating modules to implement SEPBP FLASH into a commercial TPS opens up the possibility of more widespread investigation of FLASH and lays the groundwork for future clinical translation. PURPOSE: To implement, investigate, and benchmark the capacity of a commercial TPS research extension for BP FLASH SBRT treatment planning by studying the dosimetric properties and FLASH ratio for critical organs-at-risk (OARs) at several sites.
methodsA 250 MeV clinical proton beam model was commissioned in the Eclipse TPS (Varian Medical Systems, Palo Alto, USA). BP FLASH fields were single-layer maximum-energy beams with a universal range shifter (URS) and field-specific range compensators (RCs). RCs for each beam angle were included as contours within the structure set, while the URS was modeled in the PBS beamline. Spotmaps were created using Lloyd's algorithm with minimum monitor units (MU)-based spacing to ensure plan quality and preserve FLASH coverage for critical OARs. Inverse optimization while preserving minimum MU constraints was done with scorecard-based optimization. Fifteen SBRT cases from three anatomical sites (liver, lung, base-of-skull [BOS]) previously treated at the New York Proton Center were re-optimized using this method, and dosimetric characteristics of BP plans were compared to clinically treated plans. FLASH ratios for critical OARs were evaluated for BP FLASH plans.
resultsThe dose distributions, including target uniformity, conformity index (CI), and DVHs, showed no significant difference in clinically-used metrics between BP FLASH and clinically delivered plans across all anatomical sites. Mean 40 Gy/s FLASH ratios for critical OARs were above 84% for all but one OAR with 2 Gy threshold and above 98% for all OARs with 5 Gy threshold. D
conclusionsInverse planning using a single-energy BP FLASH technique based on sparse spots and ultra-high minimum MU/spot can achieve intensity-modulated proton therapy (IMPT)-equivalent quality and sufficient FLASH coverage. This successful prototype brings us closer to commercial implementation and may increase the availability of proton FLASH dosimetry studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.